P2Y 12 inhibitors in cardiovascular disease: Focus on prasugrel

Annals of Pharmacotherapy

Volumn 43, Issue 1, 2009, Pages 64-76

  Scott, Day Marice ^a   Norwood, Rhonda M ^a   Parra, David ^b,c  

^a PALM BEACH ATLANTIC UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

CS 747; LY640315; P2Y 12; Prasugrel; Thienopyridine

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTITHROMBOCYTIC AGENT; ASPARTATE AMINOTRANSFERASE; CLOPIDOGREL; DRUG METABOLITE; FIBRINOLYTIC AGENT; HEPARIN; KETOCONAZOLE; LANSOPRAZOLE; PRASUGREL; PRODRUG; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; R 138727; R 95913; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; UNCLASSIFIED DRUG; WARFARIN; PIPERAZINE DERIVATIVE; PURINERGIC P2 RECEPTOR; THIOPHENE DERIVATIVE;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION TEST; LOADING DRUG DOSE; NEUTROPENIA; PRIORITY JOURNAL; PURPURIC RASH; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANIMAL; DRUG ANTAGONISM; METABOLISM; METHODOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; THIOPHENES;

EID: 58549089180     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G726     Document Type: Review

References (56)

1. Mackay J, Mensah G, eds. The atlas of heart disease and stroke. Geneva: World Health Organization, 2004:1-112.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
3. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-7.
4. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
5. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
6. Wenaweser P, Dörffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748-52.
7. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005;45:1157-64.
8. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.
9. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59:295-302.
10. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effects on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827-32.
11. Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 2006;19:439-48.
12. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-50.
13. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657-66.
14. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773-7.
15. Gurbel PA, Tantry US. Drug insight: clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 2006;3:387-95.
16. Siller-Matula J, Schror K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. J Throm Haemost 2007;97:385-93.
17. Mammen E, Gachet C, Cattaneo M. The platelet P2 receptors. Semin Thromb Hemost 2005;31:127-8.
18. 12 receptor antagonist activity. Semin Thromb Hemost 2005;31:184-94.
19. i-linked P2T antagonist, CS-747. Br J Pharmacol 2001;132:47-54.
20. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096-104.
21. Payne CD, Brandt JT, Weerakkody G, et al. Superior inhibition of platelet aggregation following a loading dose of CS-747 (Prasugrel, LY640315) versus clopidogrel; correlation with pharmacokinetics of active metabolite generation (abstract). J Thromb Haemost 2005;3:952.
22. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006;34:600-7.
23. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-41.
24. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9-16.
25. Jakubowski JA, Payne CD, Brandt JT, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 2006;47:377-84.
26. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng Med 2007;357:2001-15.
27. Daiichi Sankyo and Eli Lilly. Study protocols will be amended in two small early-phase prasugrel studies [press release]. October 24, 2007. www.prnewswire.com/cgibin/micro-stories.pl?ACCT=916306&TICK=LLY&STORY=/ www/story/10-24-2007/0004689575&EDATE=Oct+24,+2007 (accessed 2008 May 28).
28. 12 inhibitor: a single ascending dose study in healthy humans. Platelets 2006;17:209-17.
29. 12 inhibitor: a multiple-dose study in healthy humans. Platelets 2006;17:218-26.
30. Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007;63:421-30.
31. Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 2007;100:331-6.
32. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50:555-62.
33. 12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-73. DOI 10.1161/CIRCULATIONAHA.104.502815
34. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-84.
35. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI), Phase II trial. Ann Intern Med 1991;115:256-65.
36. Serebruany VL, Midei MG, Meilman H, Malinin AI, Lowry DR. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J 2006;82:404-10.
37. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-73.
38. Serebruany VL. Prasugrel, clopidogrel, and combining Swedish apples with American oranges. Eur Heart J 2006;27:1886-7.
39. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29:21-30.
40. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention; the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923-32.
41. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002;288:2411-20.
42. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005;111:2099-106.
43. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.
44. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of arandomised trial. Lancet 2008;371:1353-63.
45. Murphy SA, Antman EM, Wiviott SD, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008;29:2473-9.
46. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38. Circulation 2008;118:1626-36.
47. Farid NA, McIntosh M, Garofolo F, et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/ tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:169-79.
48. Farid NA, Payne CD, Ernest CS 2nd, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol 2008;48:53-9.
49. Diener HC, Bogousslavsky J, Brass LM, et al., on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2008;36:1227-32.
50. Package insert. Plavix (clopidogrel). Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, 2007.
51. Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008;36:1227-32.
52. Jakubowski JA, Payne CD, Weerakkody GJ, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol 2007;49:167-73.
53. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-9.
54. Serebruany VL, Midei MG, Meilman H, Malinin AI, Lowry DR. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. Int J Clin Pract 2006;60:863-6.
55. Daiichi Sankyo and Eli Lilly. Daiichi Sankyo, Lilly announce new prasugrel head-to-head Phase III study against clopidogrel [press release]. November 4, 2007. http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=273035 (accessed 2008 May 28).
56. Clinical Trials.gov www.clinicaltrials.gov/ct2/show/NCT00699998 (accessed 2008 Jun 16).